| Year |
Citation |
Score |
| 2023 |
Ling W, Johnson SK, Mehdi SJ, Alapat DV, Bauer M, Zangari M, Schinke C, Thanendrarajan S, van Rhee F, Yaccoby S. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers. 15. PMID 37760488 DOI: 10.3390/cancers15184519 |
0.535 |
|
| 2023 |
Mehdi SJ, Ghatak K, Ling W, Johnson SK, Epstein J, Nookaew I, Zangari M, Schinke C, Thanendrarajan S, van Rhee F, Yaccoby S. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia Research. 133: 107355. PMID 37499483 DOI: 10.1016/j.leukres.2023.107355 |
0.511 |
|
| 2020 |
Gai D, JP S, Shen X, Chen J, Li C, Peng B, Qiang Y, Yaccoby S, Zangari M, van Rhee F, Tricot GJ, Chen L, Shaughnessy J, Zhan F. CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction Blood. 136: 21-21. DOI: 10.1182/blood-2020-140568 |
0.553 |
|
| 2019 |
Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, et al. Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma. Haematologica. PMID 31221783 DOI: 10.3324/Haematol.2019.217927 |
0.349 |
|
| 2019 |
Mehdi SJ, Johnson SK, Garg TK, Ashby C, Zangari M, Schinke CD, Thanendrarajan S, Epstein J, Walker BA, Rhee Fv, Yaccoby S. The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells Blood. 134: 4412-4412. DOI: 10.1182/Blood-2019-127382 |
0.365 |
|
| 2018 |
Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British Journal of Haematology. PMID 30408155 DOI: 10.1111/bjh.15669 |
0.556 |
|
| 2018 |
Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. PMID 29784643 DOI: 10.1182/Blood-2018-04-842880 |
0.338 |
|
| 2018 |
Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson S, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan G. The pattern of Mesenchymal stem cell expression is an independent marker of outcome in multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563136 DOI: 10.1158/1078-0432.Ccr-17-2627 |
0.465 |
|
| 2018 |
Mehdi SJ, Johnson SK, Khan S, Ling W, Shelton R, Epstein J, Rhee Fv, Zangari M, Schinke CD, Thanendrarajan S, Walker BA, Ashby C, Davies FE, Morgan G, Yaccoby S. Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors Blood. 132: 1929-1929. DOI: 10.1182/Blood-2018-99-116455 |
0.579 |
|
| 2018 |
Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke CD, Thanendrarajan S, Davies FE, Morgan G, Yaccoby S. Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes Blood. 132: 4448-4448. DOI: 10.1182/blood-2018-99-115244 |
0.482 |
|
| 2017 |
Yaccoby S. Two States of Myeloma Stem Cells. Clinical Lymphoma, Myeloma & Leukemia. PMID 29066162 DOI: 10.1016/J.Clml.2017.09.020 |
0.47 |
|
| 2017 |
Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, et al. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. PMID 28550191 DOI: 10.3324/Haematol.2017.168872 |
0.33 |
|
| 2017 |
Schinke C, Hoering A, Wang H, Carlton V, Thanendrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, ... ... Yaccoby S, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. PMID 28522572 DOI: 10.3324/Haematol.2017.165217 |
0.373 |
|
| 2017 |
Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker B, Epstein J, Zangari M, van Rhee F, Meissner T, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. PMID 28432222 DOI: 10.1182/Blood-2017-03-774422 |
0.338 |
|
| 2017 |
Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, et al. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients with Multiple Myeloma. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 28240368 DOI: 10.1002/Jbmr.3111 |
0.365 |
|
| 2017 |
Tevebaugh W, Douglas J, Walker BA, Schinke CD, Rhee Fv, Zangari M, Thanendrarajan S, Davies FE, Epstein J, Yaccoby S, Morgan GJ, Johnson SK. Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression Blood. 130: 4392-4392. DOI: 10.1182/Blood.V130.Suppl_1.4392.4392 |
0.382 |
|
| 2016 |
Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, ... ... Yaccoby S, et al. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer Journal. 6: e453. PMID 27471869 DOI: 10.1038/Bcj.2016.64 |
0.337 |
|
| 2016 |
Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, Rhee FV. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. PMID 26888183 DOI: 10.2217/Imt.15.118 |
0.359 |
|
| 2016 |
Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Molecular Cancer Therapeutics. 15: 241-50. PMID 26719576 DOI: 10.1158/1535-7163.Mct-15-0660 |
0.374 |
|
| 2016 |
Koss B, Tevebaugh W, Walker BA, Schinke C, Rhee Fv, Zangari M, Thanendrarajan S, Davies FE, Epstein J, Yaccoby S, Morgan GJ, Johnson SK. The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States Blood. 128: 4438-4438. DOI: 10.1182/Blood.V128.22.4438.4438 |
0.46 |
|
| 2016 |
Rasche L, Buros A, Weinhold N, Stein CK, McDonald JE, Chavan SS, Angtuaco E, Thanendrarajan S, Schinke C, Yaccoby S, Epstein J, van Rhee F, Zangari M, Barlogie B, Walker BA, et al. The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse Blood. 128: 4431-4431. DOI: 10.1182/Blood.V128.22.4431.4431 |
0.428 |
|
| 2016 |
Mehdi S, Khan S, Ling W, Shelton RS, Epstein J, Edmondson RD, Rhee Fv, Zangari M, Davies FE, Barlogie B, Morgan GJ, Yaccoby S. Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients Blood. 128: 3304-3304. DOI: 10.1182/Blood.V128.22.3304.3304 |
0.598 |
|
| 2016 |
Weinhold N, Chavan SS, Rasche L, Stephens OW, Patel P, Tytarenko R, Ashby C, Stein CK, Bauer MA, Wardell CP, Deshpande S, Buzder T, Molnar G, van Rhee F, Zangari M, ... ... Yaccoby S, et al. Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment Blood. 128: 3278-3278. DOI: 10.1182/Blood.V128.22.3278.3278 |
0.388 |
|
| 2016 |
Chen B, Khan S, Laska BM, Morgan GJ, Yaccoby S, Epstein J. Myeloma Exosomes Prime the Microenvironment to Support Survival and Growth of Myeloma Cells Blood. 128: 2067-2067. DOI: 10.1182/Blood.V128.22.2067.2067 |
0.563 |
|
| 2016 |
Yaccoby S, Qu P, Mehdi S, Hoering A, Epstein J, Johnson SK, Rhee Fv, Zangari M, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ. Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma Blood. 128: 2065-2065. DOI: 10.1182/Blood.V128.22.2065.2065 |
0.398 |
|
| 2015 |
Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. Bmc Cancer. 15: 864. PMID 26545722 DOI: 10.1186/S12885-015-1892-7 |
0.78 |
|
| 2015 |
Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. PMID 26022710 DOI: 10.3324/Haematol.2015.124651 |
0.392 |
|
| 2015 |
Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biology & Therapy. 16: 976-86. PMID 25996477 DOI: 10.1080/15384047.2015.1040951 |
0.533 |
|
| 2015 |
Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, et al. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia. PMID 25753926 DOI: 10.1038/Leu.2015.65 |
0.382 |
|
| 2015 |
Khan R, Apewokin S, Grazziutti M, Yaccoby S, Epstein J, van Rhee F, Rosenthal A, Waheed S, Usmani S, Atrash S, Kumar S, Hoering A, Crowley J, Shaughnessy JD, Barlogie B. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia. 29: 1195-201. PMID 25640885 DOI: 10.1038/Leu.2015.15 |
0.33 |
|
| 2015 |
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, ... Yaccoby S, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 24-36. PMID 25415285 DOI: 10.1097/Cji.0000000000000059 |
0.433 |
|
| 2015 |
Heuck C, Weinhold N, Peterson EA, Bauer M, Stein CK, Ashby T, Chavan SS, Tytarenko R, Stephens OW, Meissner T, Johann D, van Rhee F, Waheed S, Johnson SK, Zangari M, ... ... Yaccoby S, et al. The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM Blood. 126: 372-372. DOI: 10.1182/Blood.V126.23.372.372 |
0.322 |
|
| 2015 |
Malaviarachchi PA, Turner DE, Stein CK, Barlogie B, Morgan GJ, Epstein J, Yaccoby S, Johnson SK. Stem Cell-like Characteristics of MM Plasma Cells Vary By ROS Levels: Implications for Targeted Therapy Blood. 126: 1820-1820. DOI: 10.1182/Blood.V126.23.1820.1820 |
0.525 |
|
| 2015 |
Yaccoby S, Epstein J, Qu P, Rhee Fv, Zangari M, Heuck C, Davies FE, Mitchell A, Hoering A, Crowley J, Barlogie B, Morgan GJ. Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines Blood. 126: 1808-1808. DOI: 10.1182/Blood.V126.23.1808.1808 |
0.503 |
|
| 2015 |
Yaccoby S, Epstein J, Johnson SK, Qu P, Rhee Fv, Jethava Y, Stein CK, Hansen E, Mitchell A, Zangari M, Heuck C, Khan RZ, Papanikolaou X, Davies FE, Hoering A, et al. The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma Blood. 126: 1806-1806. DOI: 10.1182/Blood.V126.23.1806.1806 |
0.391 |
|
| 2015 |
Barlogie B, Rhee Fv, Zangari M, Jethava Y, Khan R, Heuck C, Schinke C, Papanikolaou X, Thanendrarajan S, Waheed S, Usmani S, Tricot G, Jagannath S, Siegel D, Epstein J, ... Yaccoby S, et al. Can we cure Multiple Myeloma by 2020? Yes Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.08.072 |
0.315 |
|
| 2014 |
Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. Blood Cancer Journal. 4: e234. PMID 25083818 DOI: 10.1038/Bcj.2014.54 |
0.798 |
|
| 2014 |
Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S. CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood. 124: 2051-60. PMID 25061178 DOI: 10.1182/Blood-2014-02-555813 |
0.785 |
|
| 2014 |
Khan R, Heuck CJ, Rosenthal A, Dhodapkar MV, Miller SE, Qu P, Johann DJ, Rhee FV, Jethava Y, Zangari M, Yaccoby S, Farmer P, Grazziutti M, Epstein J, Hoering A, et al. Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP). Journal of Clinical Oncology. 32: 8604-8604. DOI: 10.1200/Jco.2014.32.15_Suppl.8604 |
0.393 |
|
| 2014 |
Alagpulinsa D, Ayyadevara S, Yaccoby S, Reis Rs. Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition Blood. 124: 479-479. DOI: 10.1182/Blood.V124.21.479.479 |
0.483 |
|
| 2014 |
Alagpulinsa D, Ayyadevara S, Yaccoby S, Reis Rs. A Peptide Nucleic Acid Targeting Nuclear Rad51 Sensitizes Myeloma Cells to Melphalan Chemotoxicity Both in Vitro and in Vivo Blood. 124: 3529-3529. DOI: 10.1182/Blood.V124.21.3529.3529 |
0.531 |
|
| 2014 |
Zangari M, Stein CK, Yaccoby S, Yoon D, Heuck C, Jethava Y, Johann D, Khan RZ, Papanikolaou X, Rhee Fv, Davies FE, Morgan GJ, Barlogie B. Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3 Blood. 124: 3409-3409. DOI: 10.1182/Blood.V124.21.3409.3409 |
0.473 |
|
| 2014 |
Bam R, Edmondson RD, Stein CK, Li X, Ling W, Khan S, Shelton RS, Barlogie B, Yaccoby S. Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1 Blood. 124: 3403-3403. DOI: 10.1182/Blood.V124.21.3403.3403 |
0.797 |
|
| 2014 |
Li X, Garg TK, Johnson SK, Szmania S, Stivers J, Ling W, Khan S, Malaviarachchi P, Barlogie B, Rhee Fv, Yaccoby S. ATRA Upregulates Cell Surface CD1D on Myeloma Cells and Sensitizes Them to iNKT Cell-Mediated Lysis Blood. 124: 2102-2102. DOI: 10.1182/Blood.V124.21.2102.2102 |
0.527 |
|
| 2014 |
Khan RZ, Heuck C, Rosenthal A, Stein CK, Epstein J, Yaccoby S, Papanikolaou X, Jethava Y, Zangari M, Rhee FV, Dhodapkar MV, Morgan GJ, Hoering A, Crowley J, Barlogie B. Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt Blood. 124: 2078-2078. DOI: 10.1182/Blood.V124.21.2078.2078 |
0.329 |
|
| 2014 |
Phanavanh B, Malaviarachchi P, Rosenthal A, Jethava Y, Barlogie B, Sawyer J, Epstein J, Yaccoby S, Johnson SK. Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival Blood. 124: 2012-2012. DOI: 10.1182/Blood.V124.21.2012.2012 |
0.4 |
|
| 2014 |
Barlogie B, Mitchell A, Rhee Fv, Epstein J, Yaccoby S, Zangari M, Heuck C, Hoering A, Morgan GJ, Crowley J. Curing Multiple Myeloma (MM) with Total Therapy (TT) Blood. 124: 195-195. DOI: 10.1182/Blood.V124.21.195.195 |
0.429 |
|
| 2014 |
Alagpulinsa DA, Yaccoby S, Ayyadevara S, Reis RJS. Abstract 2400: Dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs), impairs homologous recombination, abrogates G2 checkpoint arrest and sensitizes myeloma cells to PARP inhibition Cancer Research. 74: 2400-2400. DOI: 10.1158/1538-7445.Am2014-2400 |
0.444 |
|
| 2013 |
Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. Plos One. 8: e74191. PMID 24066119 DOI: 10.1371/Journal.Pone.0074191 |
0.411 |
|
| 2013 |
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. American Journal of Hematology. 88: 463-71. PMID 23456977 DOI: 10.1002/Ajh.23433 |
0.797 |
|
| 2013 |
Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Experimental Hematology. 41: 547-557.e2. PMID 23435312 DOI: 10.1016/j.exphem.2013.02.008 |
0.795 |
|
| 2013 |
Bam R, Venkateshaiah SU, Li X, Khan S, Ling W, Shelton RS, Zhang Q, Barlogie B, Epstein J, Yaccoby S. Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis Blood. 122: 4432-4432. DOI: 10.1182/Blood.V122.21.4432.4432 |
0.809 |
|
| 2013 |
Venkateshaiah SU, Li X, Khan S, Ling W, Shelton RS, Epstein J, Barlogie B, Yaccoby S. Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways Blood. 122: 3118-3118. DOI: 10.1182/Blood.V122.21.3118.3118 |
0.6 |
|
| 2013 |
venkateshaiah SU, Bam R, Li X, Khan S, Ling W, Randal S S, Yaccoby S. GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts Blood. 122: 3099-3099. DOI: 10.1182/Blood.V122.21.3099.3099 |
0.771 |
|
| 2013 |
Ye S, Qiang W, Chen Y, Hu B, Zhang Q, Yaccoby S, Rhee Fv, Barlogie B, Epstein J. MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma Blood. 122: 281-281. DOI: 10.1182/Blood.V122.21.281.281 |
0.476 |
|
| 2013 |
Venkateshaiah SU, Bam R, Li X, Sharmin K, Wen L, Shelton RS, Teige I, Frendéus B, Barlogie B, Yaccoby S. Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro Blood. 122: 1926-1926. DOI: 10.1182/Blood.V122.21.1926.1926 |
0.79 |
|
| 2013 |
Bam R, Venkateshaiah SU, Li X, Khan S, Ling W, Barlogie B, Epstein J, Yaccoby S. Abstract 1648: Primary myeloma plasma cells are capable of growth in adult, normal whole human bone marrow environment . Cancer Research. 73: 1648-1648. DOI: 10.1158/1538-7445.Am2013-1648 |
0.779 |
|
| 2012 |
Li X, Ling W, Khan S, Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 27: 1635-48. PMID 22460389 DOI: 10.1002/Jbmr.1620 |
0.543 |
|
| 2012 |
Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 97: 1348-56. PMID 22419581 DOI: 10.3324/Haematol.2011.056747 |
0.6 |
|
| 2012 |
Johann D, Qu P, Sexton R, Hoering A, Epstein J, Yaccoby S, Rhee Fv, Usmani SZ, Crowley J, Barlogie B. Gene Expression Profiling (GEP) of Whole Bone Marrow Biopsies (BMB) in Multiple Myeloma (MM) – Relationship to Plasma-Cell (PC)-Based GEP-Defined Risk and Molecular Subgroups Blood. 120: 3953-3953. DOI: 10.1182/Blood.V120.21.3953.3953 |
0.464 |
|
| 2012 |
Upparahallivenkateshaiah S, Sharmin K, Wen L, Bam R, Li X, Yaccoby S. Upregulation of Lipid Metabolism Modulators in Myeloma Cells Underlines Their Progression in a Supportive Microenvironment and Linking Metabolic Pathways with Growth Signaling Blood. 120: 329-329. DOI: 10.1182/Blood.V120.21.329.329 |
0.763 |
|
| 2012 |
Li X, Ling W, Khan S, Venkateshaiah SU, Bam R, Barlogie B, Epstein J, Yaccoby S. HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease. Blood. 120: 2944-2944. DOI: 10.1182/Blood.V120.21.2944.2944 |
0.778 |
|
| 2012 |
Usmani SZ, Waheed S, Mitchell A, Crowley J, Hoering A, Petty NM, Epstein J, Heuck C, Yaccoby S, Johann D, Rhee Fv, Barlogie B. 18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials. Blood. 120: 2910-2910. DOI: 10.1182/Blood.V120.21.2910.2910 |
0.342 |
|
| 2012 |
Li X, Zhang Q, Johnson SK, Ling W, Khan S, Rhee Fv, Usmani SZ, Waheed S, Barlogie B, Epstein J, Yaccoby S. Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis Blood. 120: 1815-1815. DOI: 10.1182/Blood.V120.21.1815.1815 |
0.561 |
|
| 2011 |
Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD, van Rhee F, ... ... Yaccoby S, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells (Dayton, Ohio). 29: 263-73. PMID 21732484 DOI: 10.1002/Stem.572 |
0.578 |
|
| 2011 |
Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 96: 333-6. PMID 20952514 DOI: 10.3324/haematol.2010.031302 |
0.349 |
|
| 2011 |
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, Williams R, van Rhee F, Nair B, Usmani S, Barlogie B, Shaughnessy JD, Epstein J, Yaccoby S. Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis Blood. 118: 884-884. DOI: 10.1182/Blood.V118.21.884.884 |
0.794 |
|
| 2011 |
Qiang Y, Chen Y, Hu B, Qiang W, Heuck C, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts Blood. 118: 808-808. DOI: 10.1182/Blood.V118.21.808.808 |
0.6 |
|
| 2011 |
Li X, Johnson SK, Ling W, Khan S, John LS, Barlogie B, Shaughnessy JD, Yaccoby S. Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease Blood. 118: 627-627. DOI: 10.1182/Blood.V118.21.627.627 |
0.566 |
|
| 2011 |
Venkateshaiah SU, Khan S, Ling W, John LS, Bam R, Li X, Yaccoby S. Stearoyl CoA Desaturase 1 (SCD1) Is Upregulated in Rapidly Growing Myeloma Cells and Is Required for Cell Proliferation Blood. 118: 3943-3943. DOI: 10.1182/Blood.V118.21.3943.3943 |
0.795 |
|
| 2011 |
Bam R, Ling W, Khan S, Venkateshaiah SU, Li X, van Rhee F, Nair B, Usmani S, Barlogie B, Shaughnessy JD, Epstein J, Anaissie EJ, Yaccoby S. Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease, Blood. 118: 3941-3941. DOI: 10.1182/Blood.V118.21.3941.3941 |
0.782 |
|
| 2011 |
Garg TK, Khan J, Szmania S, Greenway AD, Lingo JD, Moreno-Bost A, Stone K, Hoering A, Woods E, Nair B, Bellamy W, Campana D, Yaccoby S, Barlogie B, Epstein J, et al. Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma Blood. 118: 2918-2918. DOI: 10.1182/Blood.V118.21.2918.2918 |
0.548 |
|
| 2011 |
Johnson SK, Stewart P, Yaccoby S, Zhan F, Barlogie B, Shaughnessy JD. Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival Blood. 118: 1813-1813. DOI: 10.1182/Blood.V118.21.1813.1813 |
0.59 |
|
| 2010 |
Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD, Yaccoby S. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. Plos One. 5: e15233. PMID 21188144 DOI: 10.1371/Journal.Pone.0015233 |
0.537 |
|
| 2010 |
Jia D, Koonce NA, Halakatti R, Li X, Yaccoby S, Swain FL, Suva LJ, Hennings L, Berridge MS, Apana SM, Mayo K, Corry PM, Griffin RJ. Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiation Research. 173: 809-17. PMID 20518660 DOI: 10.1667/Rr1734.1 |
0.456 |
|
| 2010 |
Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. British Journal of Haematology. 149: 311-21. PMID 20230410 DOI: 10.1111/J.1365-2141.2010.08141.X |
0.561 |
|
| 2010 |
Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leukemia & Lymphoma. 51: 213-20. PMID 20038269 DOI: 10.3109/10428190903503438 |
0.604 |
|
| 2010 |
Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 115: 61-70. PMID 19837979 DOI: 10.1182/Blood-2009-03-210526 |
0.559 |
|
| 2010 |
Li X, Ling W, Khan S, Wang Y, Pennisi A, Barlogie B, Shaughnessy J, Yaccoby S. Systemically Injected Mesenchymal Stem Cells Traffic to Myelomatous Bone and Inhibit Bone Disease, and Intralesionally Promotes Bone Formation and Delays Myeloma Progression During the Disease Active Stage or Remission Blood. 116: 980-980. DOI: 10.1182/Blood.V116.21.980.980 |
0.609 |
|
| 2010 |
Bam R, Pennisi A, Li X, Khan S, Wang Y, Ling W, Barlogie B, Shaughnessy J, Yaccoby S. Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease Blood. 116: 447-447. DOI: 10.1182/Blood.V116.21.447.447 |
0.787 |
|
| 2010 |
Pennisi A, Li X, Barlogie B, PhD JS, Yaccoby S. Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone Blood. 116: 4063-4063. DOI: 10.1182/Blood.V116.21.4063.4063 |
0.574 |
|
| 2010 |
Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy J, Rhee Fv, ... ... Yaccoby S, et al. Human Placenta-Derived Adherent Cells Delivered Intralesionally Inhibit Myeloma Bone Disease and Tumor Growth, While Intravenously Are Capable of Trafficking to Myelomatous Bone. Blood. 116: 3717-3717. DOI: 10.1182/Blood.V116.21.3717.3717 |
0.575 |
|
| 2010 |
Entin I, Yaccoby S, Zhining W, Shaughnessy J, Barlogie B, Epstein J. Myeloma Cell Interaction with Osteoclasts and Mesenchymal Stem Cells Reveals Genes Associated with Post Relapse Survival. Blood. 116: 2957-2957. DOI: 10.1182/Blood.V116.21.2957.2957 |
0.476 |
|
| 2010 |
Li X, Ling W, Khan S, Wang Y, Pennisi A, Barlogie B, Shaughnessy J, Yaccoby S. Systemically Transplanted Human Bone Marrow Mesenchymal Stem Cells Primarily Traffic to Mesenteric Lymph Nodes Blood. 116: 2580-2580. DOI: 10.1182/Blood.V116.21.2580.2580 |
0.439 |
|
| 2010 |
Yaccoby S. The role of the proteasome in bone formation and osteoclastogenesis Ibms Bonekey. 7: 147-155. DOI: 10.1138/20100439 |
0.319 |
|
| 2009 |
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, ... ... Yaccoby S, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics. 8: 2616-24. PMID 19723891 DOI: 10.1158/1535-7163.Mct-09-0483 |
0.537 |
|
| 2009 |
Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, Yaccoby S. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 114: 1803-12. PMID 19597185 DOI: 10.1182/Blood-2009-01-201954 |
0.581 |
|
| 2009 |
Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Letters. 284: 175-81. PMID 19446953 DOI: 10.1016/J.Canlet.2009.04.022 |
0.6 |
|
| 2009 |
Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N, Yaccoby S. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. British Journal of Haematology. 145: 775-87. PMID 19388929 DOI: 10.1111/J.1365-2141.2009.07696.X |
0.554 |
|
| 2009 |
Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology. 84: 6-14. PMID 18980173 DOI: 10.1002/Ajh.21310 |
0.548 |
|
| 2009 |
Garg TK, Szmania S, Malbrough P, Ekworomadu C, Stone K, Moreno-Bost A, Woods E, Shi J, Yaccoby S, Shaughnessy JD, Barlogie B, Campana D, Rhee Fv. Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo. Blood. 114: 953-953. DOI: 10.1182/Blood.V114.22.953.953 |
0.537 |
|
| 2008 |
Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood. 112: 159-68. PMID 18436739 DOI: 10.1182/Blood-2007-11-124164 |
0.616 |
|
| 2008 |
Qiang YW, Shaughnessy JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 112: 374-82. PMID 18344425 DOI: 10.1182/Blood-2007-10-120253 |
0.605 |
|
| 2008 |
Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. Molecular Cancer Therapeutics. 7: 500-9. PMID 18319333 DOI: 10.1158/1535-7163.Mct-07-0524 |
0.469 |
|
| 2008 |
Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 22: 406-13. PMID 18046446 DOI: 10.1038/Sj.Leu.2405048 |
0.558 |
|
| 2008 |
Pennisi A, Ling W, Li X, Chen J, Khan S, Yaccoby S. The EphrinB2/EphB4 Axis Is Dysregulated in Osteoprogenitors from Myeloma Patients and Its Activation by EphrinB2-Fc or EhpB4-Fc Affects Myeloma Bone Disease and Tumor Growth in Vivo Blood. 112: 844-844. DOI: 10.1182/Blood.V112.11.844.844 |
0.613 |
|
| 2008 |
Shaughnessy JD, Qu P, Edmondson R, Herman D, Zhou Y, Tian E, Rhee Fv, Pineda-Roman M, Alsayed Y, Anaissie E, Qiang Y, Epstein J, Yaccoby S, Williams D, Zhan F, et al. Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy Blood. 112: 733-733. DOI: 10.1182/Blood.V112.11.733.733 |
0.424 |
|
| 2008 |
Li X, Ling W, Pennisi A, Chen J, Khan S, Heidaran M, Faleck H, Hariri R, Shaughnessy J, Rhee Fv, Epstein J, Barlogie B, Yaccoby S. Human Placenta-Derived Adherent Stem Cells Prevent Bone Loss and Stimulate Bone Formation in Myelomatous Bones, and Suppress Growth of Primary Multiple Myeloma Blood. 112: 646-646. DOI: 10.1182/Blood.V112.11.646.646 |
0.581 |
|
| 2008 |
Zangari M, Pappas L, Zhan F, kumar NS, Cavallo F, Suva LJ, Tricot G, Esseltine D, Yaccoby S. Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients Blood. 112: 2783-2783. DOI: 10.1182/Blood.V112.11.2783.2783 |
0.405 |
|
| 2008 |
Yaccoby S, Zhan F, Shaughnessy J. Cell lines of hyperdiploid myeloma, are we there yet? - Response to Chng & Fonseca [3] British Journal of Haematology. 140: 580-581. DOI: 10.1111/J.1365-2141.2007.06962.X |
0.388 |
|
| 2008 |
Jia D, Halakatti R, Jackson C, Li X, Yaccoby S, Swain F, Suva L, Hennings L, Corry PM, Griffin RJ. Repression of Multiple Myeloma Growth with Combined Radiotherapy and Angiogenesis Antagonist International Journal of Radiation Oncology*Biology*Physics. 72: S64. DOI: 10.1016/J.Ijrobp.2008.06.910 |
0.329 |
|
| 2008 |
Jia D, Halakatti R, Jackson C, Suva L, Li X, Yaccoby S, Hennings L, Griffin R, Corry P. Inhibition of multiple myeloma (MM) growth and preservation of bone with combined radiotherapy and anti-angiogenic agent Bone. 43: S79-S80. DOI: 10.1016/J.Bone.2008.07.089 |
0.469 |
|
| 2007 |
Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. British Journal of Haematology. 138: 802-11. PMID 17760811 DOI: 10.1111/J.1365-2141.2007.06742.X |
0.463 |
|
| 2007 |
Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. American Journal of Hematology. 82: 831-3. PMID 17546639 DOI: 10.1002/Ajh.20961 |
0.44 |
|
| 2007 |
Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 110: 2041-8. PMID 17536013 DOI: 10.1182/Blood-2007-04-082495 |
0.411 |
|
| 2007 |
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, ... ... Yaccoby S, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1121-8. PMID 17296972 DOI: 10.1200/Jco.2006.08.5803 |
0.318 |
|
| 2007 |
Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 109: 4470-7. PMID 17255354 DOI: 10.1182/Blood-2006-11-056747 |
0.572 |
|
| 2007 |
Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 109: 2106-11. PMID 17068150 DOI: 10.1182/Blood-2006-09-047712 |
0.535 |
|
| 2007 |
Li X, Pennisi A, Yaccoby S. Small Leucine-Rich Proteoglycans (SLRPs) Are Involved in the Anti-Myeloma Response of Osteoblasts. Blood. 110: 815-815. DOI: 10.1182/Blood.V110.11.815.815 |
0.625 |
|
| 2007 |
Pennisi A, Li X, Gaddy D, Akel N, Aziz N, Yaccoby S. Inhibitors of Fibroblast Activation Protein (FAP) Inhibit Primary Myeloma Growth and Osteoclastogenesis Ex Vivo and In Vivo. Blood. 110: 813-813. DOI: 10.1182/Blood.V110.11.813.813 |
0.549 |
|
| 2007 |
Pennisi A, Li X, Zangari M, Sawyer JR, Zhan F, Barlogie B, Shaughnessy J, Yaccoby S. Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease. Blood. 110: 548-548. DOI: 10.1182/Blood.V110.11.548.548 |
0.602 |
|
| 2007 |
Li X, Pennisi A, Yaccoby S. Sphingosine-1 Phosphate (S1P) Is a Myeloma Survival Factor and Protects Myeloma Cells from Thalidomide-Induced Growth Inhibition by Counteracting Ceramide Activity. Blood. 110: 3509-3509. DOI: 10.1182/Blood.V110.11.3509.3509 |
0.43 |
|
| 2007 |
Qiang Y, Brown N, Chen Y, Yaccoby S, Barlogie B, Shaughnessy JD. Increasing Wnt3a Signaling in Myeloma Cells Inhibits the Osteolytic Phenotype and Tumor Growth In Vivo through Regulation of the RANKL/OPG Axis in Osteoblasts and Indirectly Regulates Osteoclastogenesis. Blood. 110: 3506-3506. DOI: 10.1182/Blood.V110.11.3506.3506 |
0.547 |
|
| 2007 |
Zangari M, Cavallo F, Suva L, Dilley J, Trico G, Barlogie B, Burns MJ, Passera R, Boccadoro M, Esseltine D, Yaccoby S. Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients. Blood. 110: 2719-2719. DOI: 10.1182/Blood.V110.11.2719.2719 |
0.357 |
|
| 2006 |
Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 10: 295-307. PMID 17045207 DOI: 10.1016/J.Ccr.2006.08.025 |
0.379 |
|
| 2006 |
Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clinical Lymphoma & Myeloma. 7: 109-14. PMID 17026821 DOI: 10.3816/Clm.2006.N.047 |
0.506 |
|
| 2006 |
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, et al. The molecular classification of multiple myeloma. Blood. 108: 2020-8. PMID 16728703 DOI: 10.1182/Blood-2005-11-013458 |
0.462 |
|
| 2006 |
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology. 133: 83-92. PMID 16512833 DOI: 10.1111/J.1365-2141.2006.05976.X |
0.618 |
|
| 2006 |
Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 91: 192-9. PMID 16461303 |
0.425 |
|
| 2006 |
Yaccoby S, Dillon SR, Ling W, Perkins P, Tisdale JR, Pennisi A, Saha R, Li X, Barlogie B, Tricot G, Zhan F, Shaughnessy J. Atacicept (TACI-Ig) Inhibits Growth of TACIhigh Primary Myeloma Cells in SCID-Hu Mice. Blood. 108: 842-842. DOI: 10.1182/Blood.V108.11.842.842 |
0.585 |
|
| 2006 |
Pennisi A, Ling W, Perkins P, Saha R, Li X, Barlogie B, Tricot G, Zangari M, Yaccoby S. PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone Formation In Vivo. Blood. 108: 509-509. DOI: 10.1182/Blood.V108.11.509.509 |
0.523 |
|
| 2006 |
Li X, Ling W, Saha R, Perkins P, Pennisi A, Yaccoby S. Fenretinide (4HPR) Inhibits Growth of Myeloma Cells in Their Microenvironment and Is a Potent Inhibitor of Angiogenesis and Osteoclastogenesis. Blood. 108: 3480-3480. DOI: 10.1182/Blood.V108.11.3480.3480 |
0.531 |
|
| 2006 |
Tian E, Landowski T, Stephens O, Yaccoby S, Barlogie B, Shaughnessy JD. NSC 338258 Represents a Novel Anti-Neoplastic Agent for the Treatment of Multiple Myeloma. Blood. 108: 3469-3469. DOI: 10.1182/Blood.V108.11.3469.3469 |
0.554 |
|
| 2006 |
Qiang Y, Yaccoby S, Shaughnessy JD. Expression of Wnt-3a in Myeloma Cells Inhibits the Osteolytic Phenotype In-Vivo. Blood. 108: 3420-3420. DOI: 10.1182/Blood.V108.11.3420.3420 |
0.499 |
|
| 2006 |
Colla S, Zhan F, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. JNK Regulates DKK1 Expression in Multiple Myeloma Cells. Blood. 108: 3411-3411. DOI: 10.1182/Blood.V108.11.3411.3411 |
0.615 |
|
| 2006 |
Zhan F, Colla S, Chen JB, Stewart JP, Wu X, Huang Y, Hanamura I, Burington B, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. CKS1B, Mapping to an Amplicon on Chromosome 1q21 and over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through p27 Kip1 -Dependent and Independent Mechanisms. Blood. 108: 3408-3408. DOI: 10.1182/Blood.V108.11.3408.3408 |
0.47 |
|
| 2005 |
Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7599-606. PMID 16278377 DOI: 10.1158/1078-0432.Ccr-05-0523 |
0.46 |
|
| 2005 |
Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology. 131: 71-3. PMID 16173965 DOI: 10.1111/J.1365-2141.2005.05733.X |
0.402 |
|
| 2005 |
Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods in Molecular Medicine. 113: 183-90. PMID 15968103 DOI: 10.1385/1-59259-916-8:183 |
0.487 |
|
| 2005 |
Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 105: 1303-9. PMID 15471949 DOI: 10.1182/Blood-2004-06-2141 |
0.487 |
|
| 2005 |
Zangari M, Esseltine DL, Najarian K, Elice F, Lee C-, Yaccoby S, Thertulien R, Barlogie B, Tricot G. Response to bortezomib (BOR) and bone metabolism in multiple myeloma patients Journal of Clinical Oncology. 23: 6536-6536. DOI: 10.1200/Jco.2005.23.16_Suppl.6536 |
0.423 |
|
| 2005 |
Yaccoby S, Ling W, Saha R, Zhan F, Walker R, Tricot G, Barlogie B, Shaughnessy JD. Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma. Blood. 106: 638-638. DOI: 10.1182/Blood.V106.11.638.638 |
0.561 |
|
| 2005 |
Yaccoby S, Saha R, Kozlowska E, Ge Y, Ling W, Cottler-Fox M, Barlogie B, Tricot G. Reciprocal Interaction between Megakaryocytes and Myeloma Cells Results in Increased Survival and Proliferation of Myeloma Cells. Blood. 106: 628-628. DOI: 10.1182/Blood.V106.11.628.628 |
0.539 |
|
| 2005 |
Zangari M, Najarian KB, Esseltine DL, Lee C, Barlogie B, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P. The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity. Blood. 106: 510-510. DOI: 10.1182/Blood.V106.11.510.510 |
0.401 |
|
| 2005 |
Yaccoby S, Ling W, Saha R, Yata K, Tricot G. Systemic Treatment with the Antiangiogenic Agent ABT-510 Inhibited Myeloma-Induced Microvessels and Tumor Growth in Myelomatous SCID-hu Mice. Blood. 106: 3451-3451. DOI: 10.1182/Blood.V106.11.3451.3451 |
0.481 |
|
| 2005 |
Yaccoby S, Ling W, Saha R, Barlogie B, Tricot G, Zangari M. Anti-Myeloma Response to Bortezomib Is Associated with Increased Osteoblast Activity and Bone Formation in Primary Myelomatous SCID-rab Mice. Blood. 106: 3450-3450. DOI: 10.1182/Blood.V106.11.3450.3450 |
0.543 |
|
| 2005 |
Yaccoby S, Saha R, Kozlowska E, Ge Y, Ling W, Cottler-Fox M, Barlogie B, Tricot G. Myeloma Cells Cultivate Megakaryocytes To Promote Lytic Bone Disease. Blood. 106: 2495-2495. DOI: 10.1182/Blood.V106.11.2495.2495 |
0.61 |
|
| 2004 |
Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 18: 1891-1897. PMID 15385929 DOI: 10.1038/Sj.Leu.2403513 |
0.581 |
|
| 2004 |
Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Research. 64: 2016-23. PMID 15026338 DOI: 10.1158/0008-5472.Can-03-1131 |
0.558 |
|
| 2004 |
Ge Y, Zhan F, Shaughnessy J, Barlogie B, Tricot G, Epstein J, Yaccoby S. Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells. Blood. 104: 634-634. DOI: 10.1182/Blood.V104.11.634.634 |
0.615 |
|
| 2004 |
Yaccoby S, Yata K, Ge Y, Barlogie B, Tricot G, Epstein J. The Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, Apoptosis-Resistant Phenotype. Blood. 104: 633-633. DOI: 10.1182/Blood.V104.11.633.633 |
0.543 |
|
| 2004 |
Zangari M, Lee C, Barlogie B, Najarian K, Kang S, Yaccoby S, Esseltine D, Stover JM, Tricot GJ. Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood. 104: 4910-4910. DOI: 10.1182/Blood.V104.11.4910.4910 |
0.376 |
|
| 2004 |
Yaccoby S, Yata K, Ge Y, Barlogie B, Epstein J, Tricot G. Role of Osteoclasts in Regulation of Human Hematopoietic Stem Cell Niche and Fate. Blood. 104: 4253-4253. DOI: 10.1182/Blood.V104.11.4253.4253 |
0.535 |
|
| 2003 |
Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 4: 310-4. PMID 14502254 DOI: 10.1038/Sj.Thj.6200313 |
0.567 |
|
| 2002 |
Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 100: 4162-8. PMID 12393672 DOI: 10.1182/Blood-2002-03-0939 |
0.453 |
|
| 2002 |
Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 100: 610-7. PMID 12091355 DOI: 10.1182/Blood.V100.2.610 |
0.577 |
|
| 2002 |
Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British Journal of Haematology. 116: 278-90. PMID 11841428 DOI: 10.1046/J.1365-2141.2002.03257.X |
0.593 |
|
| 2001 |
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proceedings of the National Academy of Sciences of the United States of America. 98: 11581-11586. PMID 11562486 DOI: 10.1073/Pnas.201394498 |
0.581 |
|
| 2000 |
Børset M, Hjertner Ø, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins Blood. 96: 2528-2536. DOI: 10.1182/Blood.V96.7.2528 |
0.492 |
|
| 2000 |
Børset M, Hjertner Ø, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins Blood. 96: 2528-2536. DOI: 10.1182/BLOOD.V96.7.2528 |
0.395 |
|
| 1999 |
Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 94: 3576-3582. DOI: 10.1182/Blood.V94.10.3576.422K01_3576_3582 |
0.542 |
|
| 1998 |
Yaccoby S, Barlogie B, Epstein J. Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations Blood. 92: 2908-2913. DOI: 10.1182/Blood.V92.8.2908.420A32_2908_2913 |
0.574 |
|
| 1998 |
Yaccoby S, Barlogie B, Epstein J. Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations Blood. 92: 2908-2913. DOI: 10.1182/blood.v92.8.2908 |
0.493 |
|
| Show low-probability matches. |